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Abstract
Background: Sequencing of the human genome and the subsequent analyses have produced immense volumes
of data. The technological advances have opened new windows into genomics beyond the DNA sequence. In
parallel, clinical practice generate large amounts of data. This represents an underused data source that has much
greater potential in translational research than is currently realized. This research aims at implementing a
translational medicine informatics platform to integrate clinical data (disease diagnosis, diseases activity and
treatment) of Rheumatoid Arthritis (RA) patients from Karolinska University Hospital and their research database
(biobanks, genotype variants and serology) at the Center for Molecular Medicine, Karolinska Institutet.
Methods: Requirements engineering methods were utilized to identify user requirements. Unified Modeling
Language and data modeling methods were used to model the universe of discourse and data sources. Oracle11g
were used as the database management system, and the clinical development center (CDC) was used as the
application interface. Patient data were anonymized, and we employed authorization and security methods to
protect the system.
Results: We developed a user requirement matrix, which provided a framework for evaluating three translation
informatics systems. The implementation of the CDC successfully integrated biological research database (15172
DNA, serum and synovial samples, 1436 cell samples and 65 SNPs per patient) and clinical database (5652 clinical
visit) for the cohort of 379 patients presents three profiles. Basic functionalities provided by the translational
medicine platform are research data management, development of bioinformatics workflow and analysis, sub-
cohort selection, and re-use of clinical data in research settings. Finally, the system allowed researchers to extract
subsets of attributes from cohorts according to specific biological, clinical, or statistical features.
Conclusions: Research and clinical database integration is a real challenge and a road-block in translational
research. Through this research we addressed the challenges and demonstrated the usefulness of CDC. We adhered
to ethical regulations pertaining to patient data, and we determined that the existing software solutions cannot
meet the translational research needs at hand. We used RA as a test case since we have ample data on active and
longitudinal cohort.
Keywords: Swedish Rheumatology Quality Register (SRQ), Translational medicine platform, Secondary use of clinical
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Background
As stated above, the development of genomic technologies
following the post-genomic era have resulted in immense
large-scale of data generation. However, it is not only large
volumes of DNA sequence data generated from large-scale
projects, e.g., (e.g. 1000 genome [1] and ENCODE [2]), that
pose challenges for computing infrastructures. Techno-
logical advances have opened new windows into genomics
beyond the DNA sequence. Some examples of different
types of data that can be generated today—from inside
the cell—include: DNA-methylations, SNPs, CNVs, protein
coding RNA, non-coding RNA, splice variants, histone
modifications, nucleosome positions, transcription factors
and their DNA binding sites, transcription start-sites, pro-
moters, protein-protein interactions, protein localization,
protein modifications (these are numerous), DNA binding
proteins, and metabolites. In addition clinical practice and
healthcare have produced large amounts of data describing
diseases, medications, environmental factors, and lifestyle-
related information. Clinical data stored in electronic med-
ical records is very restricted and managed differently than
research data commonly shared and available through pub-
lic repositories or scientific journals. The lack of appropri-
ate and useable computing infrastructure reduces the
utilization of data sources, which have much greater re-
search potential than is currently realized. In particular,
there is an urgent need for computing resources to connect
both molecular and healthcare data. Current challenges to
be addressed are secure and easy access to biomedical data-
bases, patient data protection, data sharing, and database
integration. The current lack of methods and systems to
bridge the gap between research and clinic information
constitute a major road-block for translational research and
for the benefit of healthcare.
The current research addresses the above challenges and
provides an informatics platform for modeling and integrat-
ing multiple data sources in the Rheumatology Research
Laboratory at the Center for Molecular Medicine (CMM),
Karolinska Institute (KI) and the clinical data at the Rheu-
matology Clinic at Karolinska University Hospital in the
other hand. The data sources at CMM are the rheumatoid
arthritis (RA) biobank (serum, EDTA-plasma and DNA),
cell registry (PBMC, SFMC, etc.), genotype variants, and
serology database for a cohort of 379 patients diagnosed
with RA (defined by ACR 1987 or later ACR/Eular 2010).
The cohort presents three profiles:
– HLA-DR genotyping.
– Genotype of 65 SNPS all predisposing for RA either
directly or in interaction with HLA.
– Detection of anti-CCP antibodies IgG antibodies
against citrullinated alpha-enclose peptide-1 (CEP-1)
and citrullinated type-II collagen (citC1III), IgG
antibodies against citrullinated vitamin.
At the Rheumatology Clinic, data about disease duration,
treatment, disease activity, and specification of the disease
are stored in the SRQ [3]. A translational medicine plat-
form that integrates all data sources is the key to making
research even more translational [4], and it will also em-
power current research to find predictive markers, such as
immunological phenotypes.
Rheumatoid arthritis
RA is a common chronic inflammatory debilitating disease
that primarily affects the synovial joints, but it may also
affect tissues and organs. For patients, quality of life and
the possibility of maintaining employment is significantly
affected. The life time risk of developing RA in Sweden is
around 2% [5], and despite the use of the new improved
therapies, the rate of sick leave in early RA is still close to
50% [6]. Risk factors for developing RA have been mapped
to both genetic and environmental factors, with the Human
Leukocyte Antigen (HLA) region and cigarette smoking
conferring the strongest risk [7]. The HLA association is
tightly linked to the emergence of a set of autoantibodies
denoted as ACPA (anti-citrullinated protein antibodies) [8],
which today are used to subcategorize this disease. Hence,
immunological studies aimed at increasing our understand-
ing of disease initiation and perpetuation needs to take into
account both the genetic and serological profile of the in-
cluded patient material.
i2b2 and STRIDE: community driven software solutions
A number of technology platform solutions are available
to manage biomedical data in translational research.
Some of them, developed by research community are re-
leased as open-source under General Public License
(GPL [9]), developed by research communities at univer-
sities and research institutes. One of the commonly used
platforms is Informatics for Integrating Biology and the
Bedside (i2b2) [10]. The i2b2 platform is funded by the
National Institutes of Health (NIH). i2b2 uses The Inter-
national Classification of Diseases (ICD) [11] as a taxo-
nomic standard to classify diseases, and it enables the
creation of formal ontologies to meet the specific re-
quirements of different research studies.
The design of i2b2 provides software platform and
scalable solutions that facilitate repurposing of clinical
data into the research setting and to secure the access
and management of patient information for research
purposes. i2b2 was implemented as a set of software
cells orchestrated in hive architecture that communicate
via web service technology in a Service-Oriented Archi-
tecture (SOA) environment. This kind of architecture
provides secure communication based on Simple Object
Access Protocol (SOAP) messages. The principle design
of i2b2 paid attention to query and data retrieval
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performance. Two predefined test cases were supported
by i2b2, as mentioned in [12]:
1. Explore patient data to find sets of patients that
would be of interest for further research, and
2. Make use of the detailed data provided by the
Electronic Medical Record (EMR) to discover
different phenotypes of the set of patients identified
(first test case) in support of genomic, outcome, and
environmental research.
Based on the Health Level 7 (HL7) data model, the Stan-
ford Translational Research Integrated Database Environ-
ment (STRIDE) represents an integrated standards-based
translational research informatics platform. It provides a
number of functionalities required in translational research
[13]. The basic building blocks of STRIDE are; a clinical
data warehouse based on the Health Level Seven (HL7)
Reference Information Model (RIM) [14], an application
development framework for building research data man-
agement applications on the STRIDE platform and a
biospecimen data management system.
In addition to the EMR, STRIDE provides biobank data
management. Similar to i2b2, STRIDE uses ICD and other
standards like Systematized Nomenclature Of Medicine
Clinical Terms (SNOMED) [15] to build the semantic
model to represent biomedical concepts and different types
of relationships. The data warehouse of STRIDE built on
Oracle 11g, the database organized in three logically clus-
tered databases; clinical data warehouse, research data man-
agement and biobanks. The schemas used based on an
Entity-Attribute-Value (EAV) model and object-oriented
data structures derived from the HL7. Different software
components of STRIDE are communicating via set of web
services in a service oriented architecture (SOA) platform.
Through the semantic layer, STRIDE support standards-
based data entry, data integration, data retrieval and data
interoperability.
Translational informatics challenges and solutions
Due to the different storage strategies for patient data and
the explosion in volume, translational informatics faces a
significant challenge in database integration. At the re-
search level, the increasing pace of molecular data-
production through high throughput technologies creates
a great demand for data management (storage, transfer, re-
trieval, processing, and interpretation). On the other hand,
patient data at the health care level is becoming more
complicated since patient records are stored in EMR and
the quality of care registry for different diseases. Re-use of
clinical data in the research setting brings data manage-
ment challenges. Data management includes not only
storage of the data, but also access restrictions and con-
trol. Researchers need to perform queries across different
data sources (patient bio samples, genetics, serology, etc.)
and clinical data (diagnosis, medications, diseases activ-
ities, life style) from healthcare facilities. Our approach is
to collect and define end-user requirements (biomedical
and bioinformatics researchers) for the study the etiology,
pathogenesis, disease course, co-morbidities, and therapies
of RA. We matched the requirements with the current
solutions and used engineering methods to implement
the system at the CMM. By selecting and imple-
menting the CDC from Oracle™ (see the method sec-
tions), we achieved our objectives and satisfied end-user
requirements.
Methods
Systematic research methods are essential to (1) determine
the services and functionality to be provided by the system,
(2) identify and understand the operational constraints (pa-
tient privacy, security, etc.), and (3) understand bioinfor-
matics workflow management and analysis.In the following
sections, we discuss different methods and techniques used
during the current study and present the results from
each method.
Universe of discourse (UoD)
We started the research by identifying sources of data and
acquiring a knowledge base. In such a domain, all entities
(objects) composing the domain and the relationship
among them were identified. This domain of knowledge is
known as the Universe of Discourse (UoD) [16], ‘a complete
range of objects, events, attributes, relations, ideas, etc. that
are assumed to exist at one occasion’. In a database man-
agement system, UoD refers to the part of the world under
study; the UoD maps all relevant aspects of the investigated
world. Its conceptualization (abstraction) must be complete
and comprehensive. To define the UoD, we used two tools:
the first was the Unified Modeling Language (UML) class
diagram, which shows all classes and their relationships;
secondly concept mapping, a technique to define concepts
and their attributes.
Class diagram
The class diagram is a UML artifact [17]. UML is a model-
ing approach system development (object oriented design
and analysis). UML was used to diagrammatically visualize
and document software modules during requirements ana-
lysis. UML provides three types of diagrams: behavior,
interaction, and structure diagrams ([18] and [19]). The
class diagram is one of the structure diagram types and was
used to model the basic elements of the software system,
their attributes, and relations. The class diagram in Figure 1
illustrates the main elements of the UoD under study. At
the heart of the class diagram is the Swedish Rheumatology
Quality Register, in which RA patient records are created
and stored. Each patient was defined with a set of personal
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health information (PHI); the two important attributes were
the civic registration number and the patient code at the
registry, which is unique to each patient.
The other classes are the RA-Biobank, serology, genotype
variant, and the cell registry.
The first three classes used the civic registration number
as the primary attribute to define patient samples, and the
secondary key attribute is the SYF number, which is a pro-
ject number and is unique to each patient. The fourth
class (cell registry) only uses the SYF number as a key at-
tributes. The relationship between all classes is specified in
the diagram.
Common vocabulary from UML class diagram
To overcome definitional and semantic problems, we built
a common vocabulary that helps to identify the concepts
(attributes) used in the class diagram. There are different
ways to model the common vocabulary for a particular do-
main, including ontology engineering methods (OEM).
OEM is used to give a formal explicit description of con-
cepts in UoD [20]. Creating domain ontology is beyond the
scope of this research since we are not going to apply any
annotation or semantic web techniques. Here, we used con-
cepts from OEM to create the common vocabulary for the
translation medicine computing platform using knowledge
acquisition and representation tools.
There is no one “correct” way for developing common
vocabulary [21]. We used the conceptual map [22] to
represent and communicate knowledge between biomed-
ical researchers, the lab technician, and the system devel-
oper. The common vocabulary consists of a set of classes.
Each class (database source) has its attributes and proper-
ties. The common vocabulary for biobanks, Swedish
Rheumatology Quality Register (SRQ) and the cell register
derived from the current representation of each of the three
sources. It should be mentioned that the SRQ (clinical data-
base) do not confirm to any of the available clinical diagno-
sis standards instead using a pre-defined common RA
diagnosis. To model the serology class we used the same
output format and naming of the attributes provided by the
Flow cytometry system. Finally, for the SNPs class , we used
Human Genome Variation Society (HGVS) nomenclature
to name the RS number for each variant [23], see Table 1.
RA biobank and cell registry
The RA biobank and cell registry were created at the CMM
and have been running and serving the purpose. The
biobank stores and manages biological specimens from pa-
tients and from relevant individuals in the population. Bio-
logical specimens are available mainly in the context of
specific research of one or several diseases (RA and MS
(multiple sclerosis)), where these studies are conducted by
one principal investigator or, in networks of clinicians and
biomedical scientists. The biobank database has been
constructed over specimen banks containing DNA, RNA,
serum, plasma and several other preparations and manage-
ment facilities, such as sample volume and box number.
Figure 1 A class diagram for the translational medicine computing platform for RA.
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For the cohort of the 379 patients, the biobank stores
more than 15000 samples, which are available for re-
searchers to run different studies. The current biobank
system was implemented in Filemaker Pro a client/server
system [24]. Filemaker Pro is a relational database system
for handling and managing small enterprise database. It
gives the user the flexibility to rapidly develop database
schemas without any consideration to integrity constrains
and database normalization. Filemaker Pro has limited
capabilities to integrate different database sources and
scale-up. A complementary source for the biobank is the
cell registry, which is an excel sheet maintained manually,
and it points to the location of cryopreserved cell samples
in the freezer and racks. Moreover, it also gives quantita-
tive information about the samples, such number of cells
available. Both the RA-biobank and the cell registry vo-
cabulary and attributes are illustrated in Figure 2.
Genotype variants and serology
Genotype variants and serology datasets contain informa-
tion derived from the biobanked specimens, and these
databases contain extensive information concerning the fol-
lowing: genotypes, both HLA-type and extensive SNP data,
and serology covering titers of different RA-related auto-
antibodies (both IgG and IgA), such as CCP, MCV,
citrullinated enolase, vimentin, fibrinogen, and type II
Table 1 List of selected SNPs
Allele frequencies
Rs number Locus Major Minor Risk
6314 HTR2A C T C
1328674 HTR2A C T T
548234 PRDM1 T C C
4781003 CIITA C T T
4535211 PLCL2 G A A
10431908 CIITA A G G
544167 C2 G T G
12746613 FCGR2A C T T
4810485 CD40 G T G
10498441 NID2 A G A
10499194 OLIG3,TNFAIP3 C T C
2064476 HLA-DPB2 A G A
706778 IL2RA C T T
2736340 BLK A G G
26232 C5orf30 C T C
540386 TRAF6 C T C
231707 C4orf8 G A A
10402677 CEACAM1 G A A
42041 CDK6 C G G
2024301 CLEC4A;POU5F1P3 A T T
3807306 IRF5 A C A
10488631 IRF5;TNPO3 T C C
3761847 TRAF1/C5 A G G
7026551 C5 A C C
11586238 CD2,CD58 C G G
231735 CTLA4 G T G
13017599 REL A G G
394581 TAGAP T C T
2263484 C21orf74 A C C
6682654 CD244
6859219 ANKRD55 C A C
13031237 REL A C C
934734 SPRED2 A G G
11676922 AFF3 A T T
3087243 CTLA4 G A G
1678542 KIF5A C G C
951500 CCL21 A G A
892188 GLP-1;FDX1L;ICAM5 C T T
1133104 CLEC4A;POU5F1P3 G T T
1980422 CD28 T C C
1859341 CEACAM8 A G G
3087456 CIITA A G G
2271077 GALNTL2 A G A
Table 1 List of selected SNPs (Continued)
2377422 CLEC4A;POU5F1P3 C T T
2476601 PTPN22 C T T
2812378 CCL21;C9orf144B A G G
2240340 PADI4 C T T
6416647 CIITA T C C
3890745 MMEL1 T C T
4272626 NHLH2 C T T
10258735 RPA3 A G G
3093023 CCR6 G A A
3218253 IL2RB G A A
6822844 IL2,IL21 G T G
7234029 PTPN2 A G G
6457620 HLA-DRA G C G
6920220 OLIG3,TNFAIP3 G A A
10413014 CEACAM8 A G G
7574865 STAT4 G T T
10468473 MAP2K4 G A A
10410147 CEACAM8 G A A
10919563 PTPRC G A G
4750316 DKFZp667F0711/PRKCQ G C G
2523451 MICA A G G
6457617 HLA-DQ C T C
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collagen [25]. These databases were maintained and man-
aged by the researchers.
DNA was extracted from EDTA blood by the salting-out
method [26]. Genotyping for HLA-DRB1 haplotypes was
conducted using the sequence-specific primer-polymerase
chain reaction method (DR low-resolution kit; Olerup SSP,
Saltsjöbaden, Sweden). DRB1*04 and DRB1*01 positive pa-
tients were further subtyped by Olerup SSP DRB1*04 (Ole-
rup SSP, Saltsjöbaden, Sweden) subtyping kits, respectively.
Genotyping for selected SNPs was performed using a
64-OpenArray platform (Applied Biosystems, Foster City,
California, USA) using chip-based TaqMan genotyping
technology. Genotyping was performed according to
manufacturer’s instructions, and genotype call were made
using AutoCaller (Applied Biosystems).
Similar to the cell registry, this database was maintained
in an excel spread sheet and has not been linked to any
other sources. Patients were the main object in this data-
base, and for each patient, different measures from syn-
ovial fluid to serum were stored. In addition, a list of
references of SNP numbers were stored and categorized
per gene risk level (Risk, Major, Minor). An illustration of
the genotype and serology vocabularies is in Figure 3. The
details of the selected SNPs are listed in Table 1.
The swedish rheumatology quality registry
The Swedish Rheumatology Quality Registry, maintained
by the Swedish Society for Rheumatology [27] is a longi-
tudinal registry of incident RA and has been in operation
since the mid-1990s. Access to the registry is restricted to
clinicians who are treating patients [28]. Researchers and
scientific studies need to access the registry and integrate
patient records to the above mentioned database. Tens of
attributes are included in the SRQ, but not all of them are
needed by biomedical researchers. In this research, we
modeled and implemented attributes that describe disease
duration (temporal) [29], disease activity, and medication.
The attributes in the RA registry are entered either by the
treating doctor or by the patient, and the RA patients are
allowed to assess their disease while at the clinic before
meeting with their doctor [30]. An illustration of the list of
the attributes from the SRQ and their relationships are
shown in Figure 4.
Data curation is a crucial process to integrate data gen-
erated in different sites and by different users. We conduct
semi-automatic curation procedures based on extract –
transform – load (ETL) method for the above sources. To
run the ETL we converted all sources into CSV file format
and run a nested SQL*Loader (sqlldr) command.
SQL*Loader is a utility for data warehouse and described
as a high performance database loads [31]. The sqlldr
allow the extraction of the CSV file into the Oracle 11 g
internal representation and then load the data into the
physical database table. The above operation is a mix of a
manual command typing as SQL statements and auto-
matic execution of extraction, transformation and load
procedures.
Before the ETL take place, the purpose of the curation
is to assure the conformance of the each source to the
corresponding target schema in the database.
Figure 2 RA Biobank and the cell registry attributes.
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Figure 3 Illustration of Genotype and serology vocabulary.
Figure 4 The Swedish Rheumatology quality register. Entities, attributes, and relationships. Dmard: Disease-modifying Anti-rheumatic Drugs.
HAQ: Health Assessment Questionnaire. DAS: The Disease Activity Score.
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System implementation
The implementation and deployment of CDC to meet the
requirements and listed in requirements matrix (results
section), divided into two parts. The first is the creation of
the back-end database schemas for each data source and
the second part was the implementation of the front-end
application and the graphical user interface.
CDC uses Oracle11g as back-end. Schemas were created
and normalized according to the database design princi-
ples and normalizations forms [16]. CDC product of
Oracle has the characteristics and functionalities listed in
the requirements matrix (see the results section). As a
front-end application, the CDC was composed of two
sub-systems, CDR- Clinical Data Repository and SCE-
Statistical Control Environment. Both CDR and SCE are
incorporated with the Oracle Health Care Data Model as
shown in Figure 5.
The clinical data repository
The Clinical Data Repository (CDR) provides a central
translational research support system that reduces time
and effort required to manage and integrate multiple data
sources generated in clinical or research settings. The
main features of CDR are as follows:
Data source integration
CDR was designed to accommodate and handle different
type of file formats and script programs written in SASW /
R-bioconductor or MATLABW. This gives flexibility for
configuring the application to handle datasets produced
by laboratory and High-throughput platforms. Data for-
mats are not limited to text files, but they can also be text-
based files (e.g., CSV, XML) as well as structured database
files. The ability to export data in different formats sup-
port interoperability with other software systems and plat-
forms, this is a required feature for data exchange and
messaging using XML formats.
CDR users are allowed to import files in many different
formats (Excel, comma delimited format, XML and text)
to be used for other types of applications or for data ex-
change between groups and collaborators. The CDR also
features version control and data providence mechanisms,
which facilitate keeping track of different files and docu-
ments that are stored in CDR.
Metadata support
Metadata is a dataset that explained the database itself
(data about data); metadata is an essential resource in any
database management system environment. CDR provides
Figure 5 Clinical development center with its components and information flow (http://www.oracle.com).
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two types of metadata: dataset-level metadata (e.g. date of
creation of the database, who create the database, owner
of the database, when its published, etc.) and entity-level
metadata (this includes information about individual attri-
butes in each database table (e.g. data type, length, range
of values, etc.). CDR support creation and documentation
of both types of metadata by capturing all data and all
changes automatically. Metadata, as a resource, improve
the quality of information stored within CDR and also en-
sured integrity of all data sources. Imported data is vali-
dated and reviewed against integrity rules implemented in
the schemas prior to transformation and storage in the
data repository.
Collaboration support and multi-user access to CDR
Inter- and intra-group collaboration is necessary within
biomedical research. Providing collaboration and data-
base sharing while maintaining patient data security and
privacy is a challenging task. Through a security model
that was discussed previously, CDR allows access to all
kinds of documents and files that are stored in the data-
base. The CDC security manager increase sharing of the
research and clinical database under safe and secure con-
ditions (Principle investigators are able to grant access to
the system for co-workers and collaborators.). During re-
quirements elicitation, this was a feature upon which the
principal investigator insisted to have.
Statistical control environment (SCE)
The statistical control environment (SCE) represents auto-
mates and tracks the statistical analysis process, providing
end-to-end traceability of data, analysis, and assists in gen-
erating different types of pre-defined and customizable re-
ports similar to CDR. SCE features meet the requirements
of bioinformatics and computational biology. The main
features of SCE are as follows:
Version control and traceability
CSE provided end-to-end traceability of the computational
experiments, and it traced the experiment with all its asso-
ciated input, programs, and output files. The traceability
and version control features are supported with a graph-
ical viewer that helps to visualize dependency relationships
among different objects in the experiment (workflow)
(also see the results section). It is important for biomedical
research that results are re-produceable, and to this end it
is necessary that a computational experiment records the
version of both data and analysis code, and any parame-
ters used.
Tracing of experiment configurations and version con-
trol are supported with a graphical interface that helps
visualize dependencies between different objects in the
experimental workflow (see also the results section). In-
tegration of version control helps avoid the proliferation
of similarly named and marginally different script files
that make reproducing old experimental configurations
very difficult.
Users of CSE are able to get up-to-date information
about the status of different objects stored in CDR at a
given point of time.
Retrospective analysis is supported in the CSE to allow
reproduction of the data and results from an early ana-
lysis. Possibilities to run retrospective analysis is of great
importance for the review process and to trace back
computational results (see [32]).
Graphical user-interface
Information architecture (IA) principles aim to create en-
vironments with logical structures that help users find an-
swers and complete their tasks [33]. IA is concerned with
organization, labeling, navigation, and searching for infor-
mation [34]. CDC provides the end-user with Windows
Explorer-like interface (see Figure 6). This interface has
two primary components (panes). The left panes show dif-
ferent objects stored in the CDC under the cartage folders
and workbooks. Workbooks consist of folders that are cre-
ated by the user, such as query folder, programs folders,
etc. Each folder has to be created under a workbook, and
the types of the folder should be defined when created.
The users are only allowed to work with the workbook
that was assigned to them by the super-user (PI). The
CDC security manager can determine the security settings
and access restrictions on the study and folder levels. The
cartridge folder is read-only folder, which means that users
can explore the content, but are not allowed to perform
any writing operations.
User interface for querying different databases is based
on a drag-and-drop paradigm. The query builder allows
the user to precisely define the input to the query, the at-
tributes, and any kind of query parameter (relational Alge-
bra). Furthermore, users are allowed to join different
sources (tables) to maintain a useful query for answering a
particular question. The stored queries are editable and
able to be saved in different formats, such as SAS and
spread sheet applications.
Visual query builder
Integrating research and clinical databases for RA cohort,
researcher can perform simple queries against a single
database (e.g., RA-Biobank) or complex queries, which re-
trieve results from multiple databases using relationship
and primary keys to join tables. They can use logical oper-
ators (< , >, =>, <=, Not, like, In) to perform advance
query on the database.
A query retrieves a single or group of records for a par-
ticular patient or sample. The database aggregates the rec-
ord(s) to the patient/sample level. In the case of the RA
quality registry, the query builder supports retrieval of
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single patient visits to the clinic. Users can search for a
particular SNP, and the result will be extracted from the
genotype variants database. To find the risk level of the
SNPs, users need to search the genotype reference table,
where all SNPs are classified into three categories (Risk,
Minor, Major).
The visual query builder generates the corresponding
Structured Query Language (Sql) statement, and through
the mapping process, the Sql statement is executed on the
databases. This reduces the complexity of writing Sql
statements for non-technical users.
The result is presented to the user in a table format,
with columns for each query parameter and rows for each
returned value. The user can sort the table by clicking on
the column header and selecting “sort type”. In addition,
users can remove any of the column headers as long as
they are not required. The Sql statement and the results
can be saved for future use, or they can be exported to dif-
ferent formats and platforms (The query process is illus-
trated in Figure 7).
Results and discussion
Requirements matrix
In order to facilitate efficient integration and manage-
ment of workflow, we defined a simple requirements
matrix to allow us to evaluate different software solutions
and tools. We also provided a detailed list of the tasks
from the user’s point of view and then implemented it
in CDC.
We compared i2b2, STRIDE and CDC (see section i2b2
and STRIDE: community driven software solutions) and
how each of them supports the listed requirements in
Table 2.
Each of the three platforms was developed on specific
software architecture. While i2b2 and STRIDE composed
of different cells communicating via web service and
TCP/IP protocol. CDC is a client server architecture com-
posed of a back-end and a front-end. From our experience
the latest is easy to install and maintain and demands less
engineering work.
Authorization, security, and patient’s data protection
Integrating all datasets from the RA quality registry,
biobanks, genomics, and cell registry in one data layer cre-
ates a security and authorization challenge. The security
requirements on patient and research databases are essen-
tial and a prerequisite to operate and run a translational
medicine platform. A security system based on user roles
is essential to ensure that the users can only access infor-
mation that they are authorized to access. Study level per-
mission is among the best solutions: Scientist ‘X’ is
authorized to access the database created for a particular
study. PIs can act as super-users to grant access to their
collaborators and assistants.
Figure 6 Information architecture and user interface of CDR.
Abugessaisa et al. Journal of Translational Medicine 2013, 11:85 Page 10 of 17
http://www.translational-medicine.com/content/11/1/85
Identifiable patient data cannot be used in research set-
tings. Anonymity, in other words, the removal of per-
sonal health information, such as personal identification
numbers, names, hospital names, and treating physician
names, were removed, and new identification keys were
created to facilitate the link between different patient
records.
According to Health Insurance Portability and Account-
ability Act (HIPPA) identifiable fields within any EMR (Per-
sonal Health Information) are divided into two categories
(1) direct attributes which are linked directly to individual
or indirect ones such as age, address. See Figure 8.
All attributes in Table 3 (RA-Biobank and SRQ) are re-
moved and replaced with artificial pseudocode generated
from the Swedish personal number. This pseudocode will
be useful for tracking back the patient, through this
process we granted the protection of the individual priv-
acy and allowed the researchers to access clinical data
through the platform in a secure way.
To assure high level of security, the generation of the
pseudocode was performed outside the platform and be-
fore database uploads to the server.
The research group obtained ethical permit from the eth-
ical committee at Karolinska Institutet to run the research.
Figure 7 Visual query builder implementation in CDC.
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Patients' consent form collected and stored in the Rheuma-
tology clinic. Currently there is no support for handling pa-
tients consent in the current version of CDC. Handling of
the patient’ consent has not been expressed as a require-
ment when we defined the system functional requirements
for this proof of principle study. CDC as a software plat-
form is able to expand its capabilities and services to allow
the storage of the patient’ consent forms.
The de-identification process represents the first secur-
ity layer in this system, and this complemented with more
layers to protect the privacy and also the intellectual prop-
erty rights and ownership of the database. In the rest of
the section we are going to discuss more about the secur-
ity protocol implemented in the system.
In addition to the above, advanced encryption tech-
niques were embedded in CDC to encrypt user names
and passwords stored in different system directories.
Users granted the necessary credentials are able to access
the system either inside the CMM firewall at Karolinska
University Hospital or as remote users outside CMM via
virtual private network (VPN).
As a good practice, the database server was isolated
from the application server, which has both advantages
and disadvantages and has been debated within server
consolidation and multi-tier-architecture. The security
architecture and setup illustrated in Figure 9.
The system was installed on a WindowsW 2008 server
and accessible through remote access desktop connection,
where users needed to have access to the Remote Access
Desktop (RAD) provided by the system administrator.
This represents the first level credential prior to accessing
the CDC. The second password was provided by the PIs
to their team members or collaborators, and the PI is able
to specify the duration and validate the credential given to
specific users. All tasks executed by the users were tracked
and logged. Operations, such as deleting a folder or word-
book, were only possible if the user was granted the re-
quired permission from the group leader.
Table 2 List of requirements and a comparison with existing solutions
Requirements Description CDC STRIDE i2b2
R1 Database loading and integration The platform should provide a visual and easy-to-use user interface to load and
transfer data across all studies. The user should be protected from error by having the
system validate the source data files before loading them into the database(s).
√ X X
R2 User-role authentication System and application level authentication techniques should be supported, the PI
wants to grant access to his/her co-workers and collaborator and define specific role
and privilege.
√ √ X
R3 Support for bioinformatics work
flow developments
Having all the data loaded into the database, the platform should support
development of bioinformatics workflow with less scripting effort.
√ X X
R4 Visual Query Builder The platform should provide a query builder to easily create and execute queries
against the database tables contained in the study.
√ √ √
R5 Data export The platform should allow exporting query results into different formats, e.g., CSV,
spreadsheet
√ √ √
R6 Version control and traceability The platform should offer version control for all datasets that are stored in the
database. Multiple versions of each file are necessary for traceability between inputs
and outputs maintained so that the user can view the earlier versions of each file.
√ X X
R7 Minimal programming effort The integration of different databases (e.g., biobank, clinical, genotype, etc.) and
development of workflow must be easy and require as little programming effort as
possible.The platforms should support integration of scripts, e.g., R-script code into
the bioinformatics analysis workflow.
√ X X
R8 Source schema customization
and metadata management
The platforms should support creation and documentation of metadata for all data
files.
√ √ √
R9 Dashboard display for studies With a single click on the list of studies, the PI can navigate to different studies
running in his/her group and its associated databases.
√ √ √
R10 Installation The customization and installation effort is minimal. √ X X
Total of 10 requirements 10 5 4
Figure 8 Classification of personal health information (PHI).
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System usability and test cases
To demonstrate CDC usability, we selected and presented
two scenarios (test cases). The two scenarios shows the
real need for data integration and also potential types of
queries that can run across multiple data sources.
Scenario I: biomedical research: cross-sources search
and query
Ease of use and query generation are important features
that are required by end-users with less experience when
constructing query commands. Through the CDC visual
query builder, biomedical researchers are able to compose
and run a query across data sources. CDC is windows
based and the graphical user interface (GUI) uses the same
paradigm of interaction as all GUI. The biomedical
researcher familiar with windows applications is able to
run the queries by drag and drop techniques and they
don’t need to write a single code statement or script. We
provided a user manual that help and explain necessary
steps to run a query and visualize the results see Figure 7.
The following query plan shows an example of how a
sample was selected based on HLA (Human Leukocyte
Antigen) type and a precondition of having a number
of cells greater than 50.606 and SNP rs2064476 = AG
and GG:
Select
RS2064476,GTA_71.
SYFNR, GTA_71.
ANTCELLER_MILJ,GTA_71.
Table 3 List of PHI per data sources
Data sources Identifiable attributes
RA-Biobank Personnummer - Civic registration number
Efternamn – last name
Förnamn- first name
Swedish Rheumatology Quality Register Personnummer - Civic registration number
Patientkod: patient registration number in the registry
Namn: full name
registrerad_pa_mottagning: clininc address
Figure 9 Security layers of the system.
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FRYS_POS,GTA_75.
HLA_TYPE,GTA_71.
PROVSORT,GTA_75.
CCP_SERUM
From
GT_GENOTYPEVARIANTGTA_75, GT_CELLREGISTRY
GTA_71
Where
HLA_TYPE = ('*01/*04','*03/*04','*04','*04/*04','*04/*07','
*04/*08','*04/*09','*04/*10','*04/*11','*04/*12','*04/*13','*04/
*14','*04/*15','*04/*16')
AND
GTA_71.ANTCELLER_MILJ >= '50'
AND
GTA_75.RS2064476 in ('AG','GG'))
The XML schema for the above query is illustrated in
standard XML format (XML_HLA_query.xml) and the
application schema (XML_HLA_query.xsd ) are available
in appendix 1
The result of the above query plan illustrated in
Table 4:
Scenario II: bioinformatics application: for comparing
antibodies vs. SNP
The CDC statistical development center allows the devel-
opment of programs written in different programming/
scripting languages (SASW, S-PLUSW, R- bioconductor,
MATLABW, or PFSW).
Based on CDC workflow capabilities, an analytical pipe-
line was defined to report a very detailed and specific ana-
lysis. This pipeline was incorporated in two parts: the first
part queries the patients of interest, and the second part
runs an R-script in the SCE to identify genotypes (SNPs)
of interest.
The analysis of the query’s output (QO) was performed
by using a R-script, the R-script performs the following
tasks sequentially:
1) Basic statistical summary of QO (such as prevalence,
mean, standard deviation);
2) Classification of the SNPs as major, minor and/or
risk allele comparing the classification with the
provided (if provided) QO;
3) Computing the odds ratio for the different SNPs and
the different antibodies; and
4) Plotting, for each antigen, those SNPs that are
statistically associated (after false-discovery rate
correction) as risk alleles.
The above bioinformatics study aim is to investigate
how non-DRB1 genetic polymorphism may contribute
to the development of certain serological types of RA in
individuals with defined DRB1 genotypes.
Improve research data management & collaboration
among groups
In addition to the data integration possibilities, the imple-
mentation of CDC improves research data management.
Firstly, CDC provide flexible and scalable infrastructure,
which will allow management of in-house research data-
bases (Biobanks, serology, and genetics). Secondly, it in-
creases collaboration across different research groups
within CMM working in different therapeutic areas. Im-
portantly, the platform will automate exchange of diverse
data among research groups. Thirdly, it enabled access to
the clinical data stored in the quality of care registry at the
clinic through an intuitive and usable system.
We also summarized the road-blocks in scaling-up the
solutions to other diseases as the following:
Absence of data management methodology
One of the main obstacles to running a software solution
for data integration is the lack of a methodological and
systematic approach to capture, store, and analyze bio-
medical and clinical data. Currently, individual researchers
use their own ad-hoc systems for storing raw data and re-
sults. The software solution needs to provide an efficient
and systematic way for handling a large number of data-
bases. Verification of different data sources, which may be
in different formats and media, can be an additional task
in the process (tractability, version control, and quality
control). Verification and version control of data files have
Table 4 Result of query implemented in CDC visual query builder
Rs2064476 Syfnr Number of cell in million Freezer position HLA type Sample type Ccp serum
AG SyF0420 53 01:G09 *04/*15 SFMC 938.9
AG SyF0420 53 01:G10 *04/*15 SFMC 938.9
AG SyF0420 53 01:H01 *04/*15 SFMC 938.9
AG SyF0420 53 01:H02 *04/*15 SFMC 938.9
AG SyF0420 53 01:H03 *04/*15 SFMC 938.9
AG SyF0420 53 01:H04 *04/*15 SFMC 938.9
AG SyF0420 53 01:H05 *04/*15 SFMC 938.9
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a direct impact on bioinformatics and upstream analysis.
The lack of an appropriate version control system and
quality control procedures reduces the usability of the
available data and increases the time required for data cur-
ation and preprocessing procedures ([35-37]).
Data linkages and quality of information flow
Biomedical data are captured and stored by individuals
(biobankers, biologists, research nurses, lab technicians).
Without proper indexing and metadata on datasets and
attributes, this will affect data access, integration, and
linkages between different data sources for a particular
patient or sample [38]. Ideally, since there are a number
of data sources available, it is important to note that the
data sources should be linked (using join/primary keys)
and indexed in a way that makes such data retrieval pos-
sible and easy. To obtain maximum value from the data,
structured and accessible metadata is required. Proper
indexing and linking of different data sources will con-
tribute to the quality of information flow.
Absence of metadata
There are number of potential problems associated with
the definition of individual attributes (fields). For example,
only the data owner (researcher) can interpret the naming
convention, which, in addition to the lack of metadata, will
reduce the utilization and reusability of the research data
by collaborators. This is one of the major difficulties that
we faced during the conceptual and physical design of the
schemas. Ad-hoc naming and codes affected the quality
and re-usability of the datasets. This is due to the fact that
no data dictionary is in place, and researchers have less
time to pick appropriate names for attributes from avail-
able ontologies or thesauruses. One attribute has more
than one name among the different sources. Table 5 shows
examples of the same attribute has different name in dif-
ferent database sources, which causes a semantic problem
during integration.
The willingness of individual PIs and researchers to
share their data and collaborate is the cornerstone of a
successful and effective information sharing system. In
addition, attributes, and metadata should be defined and
agreed upon; this data set can be regarded as common
vocabulary, which is essential for comparing the analysis
results in different experiments and laboratories.
Individual’s genomics information
Protecting individual’s genomics information become a
challenge and debated in ([39-43]). There is no technical
solution to protect re-identification of individuals, as has
been proved in [44] the availability of summary level allele
frequency for two matched sample groups and the gen-
ome profile of one of the participants (subject of interest),
will make it easy to re-identification of individuals (sub-
ject/ person). The current trends in genomics database try
to hide some of the genotype / phenotype information to
reduce the risk of re-identification of individual.
Conclusions
In this research we addressed the challenges facing bio-
medical and clinical researcher in a translational research
environment.
The implementation of CDC as a translational informat-
ics platform integrates clinical and biomedical databases
for Rheumatoid Arthritis. We developed a requirements
matrix that captures the requirements of end users. We
matched the matrix with available technologies, and we
compared CDC against community-driven translational
platforms (i2b2 and STRIDE). Then, we implemented
CDC, the architecture of which provided the requirements
for the two classes of end users, biomedical researchers
and bioinformaticians. Through CDC, biomedical investi-
gators are able to store, access, and retrieve sample data-
bases from the biobanks and integrate it with the genetics
and serology data for the cohort under study. Additionally,
researchers are able to re-use clinical data from the quality
of care registry and run more complex queries across
different sources (genetics, serology, medication, diagnosis
and sample related parameters). The architecture and user
interface of CDC reduce the time spend by researchers to
preselect biological samples (from the RA biobanks) based
on clinical parameters (diseases activity, medication) in a
systematic manner. The CDC, through its visual query
builder, allows the preparation of the research material
based on both the availability of the samples, suitable
Table 5 Different naming used for same attribute in different database sources
Genotype variant Cell registry RA- Biobank
Project number SyRnr Patienter::Pat.nr. (patient number)
Personnr. + Personnr2
(Date of birth + Personal identification 4 digits number)
Patienter::Personnummer + Patienter::Pers.dat
(Date of birth + Personal identification 4 digits number)
Gender Patienter::Man_Kv
Provdatum (sample date) Provdat (sample date)
Provsort (sample type) Provtyp (sample type)
Namn (Name) Patienter::Efternamn (last name) + Patienter::Förnamn (first name)
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genotype, or serology status, and on disease parameters
from the SRQ.
Bioinformaticians are able to create a workflow and run
computation jobs based on the stored databases. We dem-
onstrated the use of the workflow and version control cap-
abilities of CDC with examples of comparing antibodies
vs. SNPs.
During the development we experienced difficulties to
collect and curate the dataset coming from different
sources. Data curation is a time consuming task and a cru-
cial process to make sure that source data files contains all
attributes with the appropriate data structure.
One of the main challenges is to provide a secure and
trustable system for biomedical researcher. We considered
all security and ethical regulations pertaining to patient
data. To assure the utilization of the system, we arranged
training sessions to the researchers; we explained and
demonstrated the functionalities by real example and lis-
ten to their question.
We used Rheumatoid Arthritis as a test case since we
have ample data readily available.
There are many opportunities for future development,
and we envision that the implementation of CDC at the
Rheumatology Unit will drastically evolve from RA to
other diseases and research groups in inflammatory and
cardiovascular diseases.
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